View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

DOJ/DEA RIN: 1117-AB78 Publication ID: Fall 2023 
Title: Expansion of Induction of Buprenorphine via Telemedicine Encounter  

DEA is promulgating regulatory changes which would clarify the rights and obligations for DEA registrants when prescribing buprenorphine to patients with Opioid Use Disorder pursuant to a telemedicine encounter which utilizes audio-only telecommunication systems.

Agency: Department of Justice(DOJ)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: No  Unfunded Mandates: No 
CFR Citation: 21 CFR 1300    21 CFR 1304    21 CFR 1306   
Legal Authority: 21 U.S.C. 802(54)(G)   
Legal Deadline:  None
Action Date FR Cite
NPRM  03/01/2023  88 FR 12890   
NPRM Comment Period End  03/31/2023 
Temporary Rule  05/10/2023  88 FR 30037   
Temporary Rule Effective  05/11/2023 
Second Temporary Rule  10/10/2023  88 FR 69879   
Second Temporary Rule Effective  11/11/2023 
NPRM  12/00/2023 
Additional Information: DEA Docket number 948
Regulatory Flexibility Analysis Required: No  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: No 
RIN Information URL:   Public Comment URL:  
RIN Data Printed in the FR: No 
Agency Contact:
Scott A. Brinks
Section Chief, Regulatory Drafting and Support Section, Diversion Control Division
Department of Justice
Drug Enforcement Administration
8701 Morrissette Drive,
Springfield, VA 22152
Phone:571 362-8209